2024

1. A Missense Variant in TP53 Could Be a Genetic Biomarker Associated with Bone Tissue Alterations

   International Journal of Molecular Sciences, Vol. 25, Núm. 3

2. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

   Haematologica, Vol. 109, Núm. 3, pp. 867-876

3. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

   Therapeutic Advances in Gastroenterology, Vol. 17

4. Clinical practice guideline on the management of vestibular schwannoma

   Acta Otorrinolaringologica Espanola, Vol. 75, Núm. 2, pp. 108-128

5. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

6. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

7. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

   United European Gastroenterology Journal

8. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

   eClinicalMedicine, Vol. 71

9. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply

   Alimentary Pharmacology and Therapeutics

10. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

11. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data

    Journal of the European Academy of Dermatology and Venereology

12. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

13. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

14. Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 3

15. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

16. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

17. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology

18. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

19. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

20. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

    HemaSphere